CLS: Immunophotonics announces status at clinicaltrials.gov for the intratumoral injection of IP-001, following thermal ablation, in patients with advanced solid tumors
LUND, SWEDEN October 19, 2020 - Clinical Laserthermia Systems AB (publ) (CLS) and Immunophotonics, Inc. have, as previously announced, a research collaboration under which a Phase 1b/2a clinical trial regarding cancer patients with certain solid tumor indications is carried out. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization.
The trial is now recruiting patients. The status of the on-going clinical trial will be updated on clinicaltrails.gov under the ID NCT03993678.
The goal for the clinical trial is to determine safety and tolerability of Immunophotoincs’ drug IP-001 in patients with thermally ablated solid tumors and to assess potential anti-tumor activity of intratumoral injection of IP-001, as an adjunct to tumor ablation. The laser ablation procedure is carried out with CLS imILT® protocol and TRANBERG®Thermal Therapy System.
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Ph: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ),develops and sells the TRANBERG®|Thermal Therapy System including specially designed sterile disposable products for minimally invasive treatment of cancerous tumors, in accordance with regulatory approvals in the EU and in the U.S. The products are marketed for image-guided laser ablation (FLA, LITT) and for treatment with the company’s interstitial laser thermotherapy, imILT®, with a potentially immune stimulating effect. The company, which is headquartered in Lund Sweden and has a subsidiary in Germany and Irvine, CA. is listed Nasdaq First North Growth Market under the ticker CLS B. Certified Adviser (CA) is FNCA Sweden AB, Ph: +46 8 528 00 399. E-mail: info@fnca.se. Further information is available on www.clinicallaser.se.